LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
89.71
+0.80 (+0.90%)
At close: 4:04PM EDT
Stock chart is not supported by your current browser
Previous Close88.91
Open88.83
Bid80.15 x 1300
Ask0.00 x 900
Day's Range88.54 - 89.87
52 Week Range73.69 - 89.87
Volume3,334,987
Avg. Volume3,820,693
Market Cap91.565B
Beta0.30
PE Ratio (TTM)83.84
EPS (TTM)1.07
Earnings DateJul 24, 2018
Forward Dividend & Yield2.25 (2.57%)
Ex-Dividend Date2018-08-14
1y Target Est91.94
Trade prices are not sourced from all markets
  • 3 Dividend Stocks That Should Pay You the Rest of Your Life
    Motley Fool4 hours ago

    3 Dividend Stocks That Should Pay You the Rest of Your Life

    These buy-and-hold dividend stocks can be counted on for income.

  • Here are Q2's 10 biggest VC-backed exits from the Bay Area
    American City Business Journals2 days ago

    Here are Q2's 10 biggest VC-backed exits from the Bay Area

    Here is a look at the 10 biggest venture-backed IPOs and acquisitions from the first half of what has been a very active year for such exits.

  • Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom
    Zacks2 days ago

    Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

    Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

  • Better Buy: Acadia Pharmaceuticals vs. Eli Lilly
    Motley Fool2 days ago

    Better Buy: Acadia Pharmaceuticals vs. Eli Lilly

    Which stock wins in a battle between a small, beaten-down biotech and an established major drugmaker?

  • New Lilly Diabetes helpline to Assist People Seeking Solutions to Insulin Affordability
    PR Newswire4 days ago

    New Lilly Diabetes helpline to Assist People Seeking Solutions to Insulin Affordability

    INDIANAPOLIS, July 12, 2018 /PRNewswire/ -- Starting August 1, a new dedicated helpline called the Lilly Diabetes Solution Center will assist people who need help paying for their insulin – such as those with lower incomes, the uninsured, and people in the deductible phase of their high-deductible insurance plans, Eli Lilly and Company (LLY) announced today. A customized suite of solutions for all Lilly insulins, including for Humalog® (insulin lispro), will be used by helpline operators to find answers that best fit the personal circumstances of patients.

  • The Sad Truth: This Biotech Investing Strategy Almost Always Works
    Motley Fool4 days ago

    The Sad Truth: This Biotech Investing Strategy Almost Always Works

    We want researchers to cure disease. But the honest truth is that you could potentially make a fortune by betting against drugmakers in this indication.

  • Barrons.com4 days ago

    [$$] Big Stock Buys in IBM, Lilly by Norway's Biggest Bank

    The last time we checked in with DnB, it had sold more than half of its investment in Intel. Norway’s largest and oldest private financial institution (established 1822) slashed its holdings in Intel (INTC) to 1.7 million shares from 3.8 million shares in the first quarter. DnB seemed to have a rethink in the second quarter, however, buying 537,300 more shares of the chip giant and raising its investment to 2.3 million shares as of June 30.

  • InvestorPlace5 days ago

    Trump Tweets Threat to Pfizer but Investors Shrug it Off

    Pfizer (NYSE:PFE) was the target of a Presidential tweet tantrum Monday over its second price hike of the year but investors shrugged it off.

  • InvestorPlace5 days ago

    Biogen Is the Right Alzheimer’s Stock … At the Wrong Time

    On Friday, Biogen (NASDAQ:BIIB) shares soared on news that one of its Alzheimer’s drug trials was showing tremendous promise. Specifically, BIIB stock jumped nearly 20% after an update on BAN-2401, a phase 2 drug that showed a statistically significant slowdown in the memory loss associated with Alzheimer’s. BAN-2401, an antibody that takes aim at the amyloid plaque in the brain that’s thought to be a key cause of Alzheimer’s, was cast into a questionable light late last year.

  • A Look at Incyte’s Product Portfolio in July
    Market Realist5 days ago

    A Look at Incyte’s Product Portfolio in July

    Incyte’s (INCY) product portfolio includes targeted therapies and immuno-therapies for oncology and non-oncology diseases. Incyte’s product portfolio includes 17 molecular targets and 19 clinical candidates. The chart below shows its revenues from collaborations since the first quarter of 2017.

  • Incyte’s Quarterly Revenue Stream
    Market Realist5 days ago

    Incyte’s Quarterly Revenue Stream

    Incyte Corporation (INCY) reported revenues of $382.3 million during the first quarter, a marginal decline in YoY (year-over-year) revenues compared to $384.1 million during the first quarter of 2017. These revenues include the product revenues from sales of Jakafi and Iclusig, royalty revenues from Jakavi and Olumiant, and milestone and contract revenues. The chart below compares the revenues for Incyte since the first quarter of 2017.

  • Better Buy: Eli Lilly and Company vs. AbbVie
    Motley Fool6 days ago

    Better Buy: Eli Lilly and Company vs. AbbVie

    Both of these pharmaceutical giants face competitive threats, but both have strong pipelines.

  • Zoetis and Abaxis Announce Antitrust Clearance for Merger
    Market Realist6 days ago

    Zoetis and Abaxis Announce Antitrust Clearance for Merger

    On July 6, Zoetis (ZTS) and Abaxis (ABAX) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

  • Alzheimer's Research Gets Glimmer of Hope, Not for First Time
    Bloomberg9 days ago

    Alzheimer's Research Gets Glimmer of Hope, Not for First Time

    For the few drugmakers that haven’t given up on the decades-long, elusive quest for a cure of Alzheimer’s disease, each piece of news is a small signpost along a possible path to success -- and billions of dollars in potential sales. This is the story of Alzheimer’s. Dramatic ups and downs have been typical, with about 200 failed attempts to find a treatment. Drugmakers are seeking to escape a maze, trying one approach, failing, then starting over with another.

  • Top Stocks Set to Disrupt the Diabetes Market
    Motley Fool9 days ago

    Top Stocks Set to Disrupt the Diabetes Market

    Revolutionary new drugs and medical devices could make these companies smart additions to your portfolio.

  • Biogen's Alzheimer Disease Candidate Succeeds in Phase II
    Zacks9 days ago

    Biogen's Alzheimer Disease Candidate Succeeds in Phase II

    Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.

  • Eli Lilly Stock’s June Performance
    Market Realist9 days ago

    Eli Lilly Stock’s June Performance

    Leading US pharmaceutical company Eli Lilly (LLY) specializes in human pharmaceuticals and animal health. The chart below shows Eli Lilly’s revenue and EPS since Q1 2017, and analysts’ estimate for Q2 2018.

  • Some Recent Pharmaceutical Mergers and Acquisitions
    Market Realist10 days ago

    Some Recent Pharmaceutical Mergers and Acquisitions

    The US pharmaceutical sector comprises drug manufacturers, drug marketers, and biotechnology companies. The chart below lists some recent mergers and acquisitions in the sector.

  • Here’s Why Analysts See a Major Upside in Acadia Pharmaceuticals
    Market Realist10 days ago

    Here’s Why Analysts See a Major Upside in Acadia Pharmaceuticals

    Acadia Pharmaceuticals (ACAD) is a biopharmaceutical company engaged in developing and bringing to market innovative medicines targeted at central nervous system disorders. Of the eight analysts covering Acadia Pharmaceuticals in July, seven have given the stock “buy” or higher recommendations, while one has given it a “hold” rating. The mean rating for the stock is 2, and its target price is $47.29, implying a potential upside of 193% over the stock’s trading price of $16.13 on July 2.

  • Go Long Pfizer Stock — It’s an Easy Pill to Swallow
    InvestorPlace10 days ago

    Go Long Pfizer Stock — It’s an Easy Pill to Swallow

    Pfizer (NYSE:PFE) is a pharma/biotech dinosaur. This stock is a survivor of decades of stock market turmoils and corrections. It currently sits on a potential long-term technical breakout point on the monthly chart.

  • Developments for Eli Lilly in June Include EASE Phase 3 Data
    Market Realist12 days ago

    Developments for Eli Lilly in June Include EASE Phase 3 Data

    Eli Lilly (LLY) recently completed the acquisition of ARMO Biosciences (ARMO). It also announced several developments for its existing products as well as products in the pipeline. In this article, we’ll discuss LLY’s developments for June, which are illustrated in the chart below.

  • Analysts’ Estimates and Recommendations for Eli Lilly in June
    Market Realist13 days ago

    Analysts’ Estimates and Recommendations for Eli Lilly in June

    Wall Street analysts expect Eli Lilly’s (LLY) second-quarter adjusted earnings per share to reach $1.29 on revenues of $6.0 billion. This forecast represents 3.4% growth in revenues compared to $5.8 billion during the second quarter of 2017.

  • Eli Lilly’s Animal Health Business
    Market Realist13 days ago

    Eli Lilly’s Animal Health Business

    Elanco, which is Eli Lilly’s (LLY) animal health arm, comprises food animal products and companion animal products. Elanco reported revenues of ~$761.0 million during the first quarter, a 1.0% decline in YoY (year-over-year) revenues compared to ~$769.0 million during the first quarter of 2017. The chart below compares the revenues for Elanco since the first quarter of 2017.

  • Eli Lilly’s Cardiovascular Product Portfolio
    Market Realist13 days ago

    Eli Lilly’s Cardiovascular Product Portfolio

    Eli Lilly’s (LLY) cardiovascular products include Adcirca, Cialis, and Effient. The company’s cardiovascular product portfolio reported lower sales during the first quarter, which resulted from lower sales of these drugs. The chart below compares the revenues for key cardiovascular products since the first quarter of 2017.

  • ACCESSWIRE13 days ago

    Blog Exposure - Eli Lilly's Taltz(R) Meets Primary Endpoint in Phase-3 Study for Treatment of Ankylosing Spondylitis

    LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want access to our free research report on Eli Lilly and Co. (NYSE: LLY) ("Eli Lilly"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LLY as the Company's latest news hit the wire. On June 28, 2018, the Company declared that Taltz® (ixekizumab) met the primary and major secondary endpoints in COAST-W, which is a Phase-3 study evaluating Taltz® for the treatment of Ankylosing Spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA). Active-Investors.com is currently working on the research report for Analogic Corporation (NASDAQ: ALOG), which also belongs to the Healthcare sector as the Company Eli Lilly.